Baxter International (BAX) Receives ‘Analyst’ Rating

Baxter International (BAX) : 11 analysts are covering Baxter International (BAX) and their average rating on the stock is 2.94, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 9 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Baxter International (BAX) : Average target price received by Baxter International (BAX) is $50.57 with an expected standard deviation of $4.54. The most aggressive target on the stock is $60, whereas the most downbeat target is $47. 7 financial analysts are currently covering the stock.


Also, UBS maintains its rating on Baxter International (NYSE:BAX). The global brokerage major raises the current price target from $48 per share to $50 per share. Analysts at the UBS have a current rating of Neutral on the shares. The rating by the firm was issued on July 28, 2016.

Baxter International (NYSE:BAX): After opening at $45.54, the stock dipped to an intraday low of $45.42 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $47.28 and the buying power remained strong till the end. The stock closed at $47.07 for the day, a gain of 3.61% for the day session. The total traded volume was 6,337,608. The stocks close on the previous trading day was $45.43.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.